# Medpace Moat

Status: stale. Policy: company-analysis-1.

Medpace demonstrates strong operating execution, an integrated clinical platform and contractual procurement discounts. The passages do not establish that these capabilities create a durable advantage over named rivals offering overlapping services. Pricing power is mixed: negotiated fees and upfront payments coexist with realized rebates, fixed-fee exposure and broad cancellation rights. This is insufficient evidence of defensibility, rather than demonstrated competitive weakness.

## intangible_assets

ClinTrak integrated with operating procedures, therapeutic expertise and a global workforce are existing capabilities that could support differentiation. Superior customer outcomes and defensibility relative to rivals remain unestablished; management's partner-of-choice statement is an assertion.

Durability: The platform requires accumulated expertise and organizational investment, but the passages do not demonstrate a durable performance lead, exclusive access or customer dependence.

Risks: Thermo Fisher Scientific Inc. also discloses integrated Phase I–IV clinical services. IQVIA Holdings Inc. discloses extensive global resources and proprietary data, although these disclosures cover its broader company. Competition for skilled staff and customer cancellation rights constrain protection.

Invalidation: The differentiation hypothesis would be undermined by comparable rival trial outcomes at lower prices, sustained losses of repeat assignments, or deterioration in delivery quality accompanying staff losses. Comparative trial outcomes and repeat-customer evidence could establish or reject the hypothesis.

Competitors: IQVIA Holdings Inc., ICON plc, PPD, Inc., Thermo Fisher Scientific Inc., Fortrea, Inc.
## cost_advantage

Minimum purchase commitments currently obtain preferential supplier pricing. This demonstrates a procurement benefit, but neither its magnitude nor a cost advantage over competitors is established.

Durability: Commitments extend through 2030 at varying expiration dates. Their duration does not establish exclusive discounts, renewal economics or a durable relative cost advantage.

Risks: Discounts require minimum commitments, which reached $29.4 million in June 2026. Cancellation-driven reductions in demand could weaken their economics. Competitors may obtain comparable procurement terms.

Invalidation: The relative-cost hypothesis would fail if comparable competitors receive equal or better net terms, or if unused commitments and related costs offset the discounts.

Competitors: IQVIA Holdings Inc., ICON plc, PPD, Inc., Thermo Fisher Scientific Inc., Fortrea, Inc.
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000006/medp-20251231.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000006/medp-20251231.htm) · 2026-02-10
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000025/medp-20260630.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000025/medp-20260630.htm) · 2026-07-23
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000012/medp-20260401.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000012/medp-20260401.htm) · 2026-04-01
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839725000017/medp-20241231.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839725000017/medp-20241231.htm) · 2025-02-11
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839724000013/medp-20231231.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839724000013/medp-20231231.htm) · 2024-02-13
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000019/medp-20260331.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000019/medp-20260331.htm) · 2026-04-23
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000023/medp-2026722exx991.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000023/medp-2026722exx991.htm) · 2026-07-22
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000017/medp-20260422exx991.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000017/medp-20260422exx991.htm) · 2026-04-22
- [https://www.sec.gov/Archives/edgar/data/1668397/000166839726000004/medp-20260209exx991.htm](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000004/medp-20260209exx991.htm) · 2026-02-09
- [https://www.sec.gov/Archives/edgar/data/1668397/000119312526257387/d162455d8k.htm](https://www.sec.gov/Archives/edgar/data/1668397/000119312526257387/d162455d8k.htm) · 2026-06-04
- [https://www.sec.gov/Archives/edgar/data/1668397/000119312526230425/d101911d8k.htm](https://www.sec.gov/Archives/edgar/data/1668397/000119312526230425/d101911d8k.htm) · 2026-05-19
- [https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm](https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm) · 2026-02-17
- [https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm](https://www.sec.gov/Archives/edgar/data/97745/000009774526000018/tmo-20251231.htm) · 2026-02-26

[JSON](https://beanvest.com/stock/medp/moat.json)